Neumora Therapeutics, Accumulated Other Comprehensive Income Over Time
| NMRA Stock | 9.77 0.10 1.03% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Neumora Therapeutics, Performance and Neumora Therapeutics, Correlation. Neumora |
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Neumora Therapeutics,. If investors know Neumora will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Neumora Therapeutics, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.20) | Return On Assets (0.38) | Return On Equity (0.77) |
The market value of Neumora Therapeutics, is measured differently than its book value, which is the value of Neumora that is recorded on the company's balance sheet. Investors also form their own opinion of Neumora Therapeutics,'s value that differs from its market value or its book value, called intrinsic value, which is Neumora Therapeutics,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Neumora Therapeutics,'s market value can be influenced by many factors that don't directly affect Neumora Therapeutics,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Neumora Therapeutics,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Neumora Therapeutics, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neumora Therapeutics,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Accumulated Other Comprehensive Income Analysis
Compare Neumora Therapeutics, and related stocks such as Ihuman Inc, Centessa Pharmaceuticals, and Alvotech Accumulated Other Comprehensive Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IH | (532 K) | (532 K) | (532 K) | (532 K) | (532 K) | (532 K) | (532 K) | (532 K) | (532 K) | 0.0 | (21.9 M) | (34.7 M) | 18.5 M | 26.1 M | 27.4 M |
| CNTA | (86 K) | (86 K) | (86 K) | (86 K) | (86 K) | (86 K) | (86 K) | (86 K) | (86 K) | (86 K) | (86 K) | 688 K | (1.5 M) | 1.5 M | 1.6 M |
| ALVO | 5 M | 5 M | 5 M | 5 M | 5 M | 5 M | 5 M | 5 M | 5 M | 5 M | 5 M | 4.7 M | 29.1 M | 41.4 M | 22 M |
| PSO | (455.3 M) | (698 M) | (640 M) | (633 M) | (684 M) | (569 M) | (635 M) | (605 M) | (556 M) | 617 M | 459 M | 400 M | 724 M | 432 M | 453.6 M |
| LINC | (432 K) | (6.7 M) | (6.8 M) | (3.6 M) | (7.5 M) | (7.1 M) | (6.1 M) | (4.5 M) | (4.1 M) | (3.5 M) | (4.2 M) | (1.2 M) | (960 K) | (36 K) | (37.8 K) |
| RGEN | (1.3 M) | 200 K | 1.9 M | 2 M | (5.8 M) | (8.6 M) | (13.7 M) | (6.4 M) | (11.9 M) | (15 M) | 2.1 M | (16.9 M) | (34.4 M) | (37.4 M) | (35.6 M) |
| XPOF | (31.7 M) | (31.7 M) | (31.7 M) | (31.7 M) | (31.7 M) | (31.7 M) | (31.7 M) | (31.7 M) | (31.7 M) | (31.7 M) | (1.5 M) | (276.9 M) | (16.4 M) | (15.4 M) | (16.2 M) |
Neumora Therapeutics, and related stocks such as Ihuman Inc, Centessa Pharmaceuticals, and Alvotech Accumulated Other Comprehensive Income description
Gains and losses not included in net income that are recorded in shareholders' equity, reflecting changes in the value of assets or liabilities that are not realized.My Equities
My Current Equities and Potential Positions
| Neumora Therapeutics, Common | NMRA |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | Massachusetts; U.S.A |
| Exchange | NASDAQ Exchange |
null 9.77
Check out Neumora Therapeutics, Performance and Neumora Therapeutics, Correlation. You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.
Neumora Therapeutics, technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.